Tvardi Therapeutics (0HTC) Financial Statements
Tvardi Therapeutics Financial Overview
Tvardi Therapeutics's market cap is currently $10.58M. The company's EPS TTM is $-2.79; its P/E ratio is -0.28; and it has a dividend yield of 0.20%. Tvardi Therapeutics is estimated to report earnings on November 12, 2026, and the estimated EPS forecast is $-0.57. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 7.14M | $ 20.97M | $ 41.87M | $ 23.03M |
| Gross Profit | $ -95.00K | $ 6.33M | $ 14.54M | $ 34.35M | $ 21.47M |
| Operating Income | $ -26.75M | $ -55.78M | $ -121.50M | $ -87.53M | $ -89.08M |
| EBITDA | $ -18.12M | $ -62.60M | $ -117.65M | $ -85.39M | $ -86.89M |
| Net Income | $ -18.21M | $ -70.87M | $ -118.51M | $ -85.47M | $ -88.44M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 30.81M | $ 37.90M | $ 22.92M | $ 43.74M | $ 167.03M |
| Total Assets | $ 32.07M | $ 43.83M | $ 27.00M | $ 45.10M | $ 247.06M |
| Total Debt | $ 201.00K | $ 44.45M | $ 368.00K | $ 2.37M | $ 3.67M |
| Net Debt | $ -20.53M | $ 6.54M | $ -22.55M | $ -19.12M | $ -9.78M |
| Total Liabilities | $ 11.13M | $ 48.42M | $ 89.06M | $ 90.15M | $ 19.53M |
| Stockholders' Equity | $ 20.95M | $ -4.59M | $ -62.06M | $ -45.05M | $ 227.52M |
| Cash Flow | |||||
| Free Cash Flow | $ -23.50M | $ -61.96M | $ -94.45M | $ -17.92M | $ -60.13M |
| Operating Cash Flow | $ -23.50M | $ -60.92M | $ -92.08M | $ -17.87M | $ -60.09M |
| Investing Cash Flow | $ -10.08M | $ 48.74M | $ 43.46M | $ -22.00M | $ -4.75M |
| Financing Cash Flow | $ 22.70M | $ -3.60M | $ 38.15M | $ 4.00K | $ 46.61M |
Currency in USD